Efficacy of modest dose irradiation in combination with long-term endocrinal treatment for high-risk prostate cancer: A preliminary report

Japanese Journal of Clinical Oncology

Volumn 34, Issue 7, 2004, Pages 420-424

  Sasaki, Tomonari ^a   Nakamura, Katsumasa ^a   Shioyama, Yoshiyuki ^a   Ohga, Saiji ^a   Urashima, Yusuke ^a   Terashima, Hiromi ^b   Koga, Hirofumi ^a   Naito, Seiji ^a   Noma, Hideya ^c   Komatsu, Kiyoshi ^c   Yamaguchi, Akito ^c   Honda, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HARASANSHIN HOSPITAL   (Japan)

Author keywords

Hormonal therapy; Prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN; ESTROGEN DERIVATIVE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CLINICAL STUDY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PELVIS LYMPH NODE; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME; ADJUVANT THERAPY; CANCER STAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; MIDDLE AGED; PROSTATE TUMOR; RADIATION RESPONSE; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 6044274254     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh059     Document Type: Article

References (20)

1. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-7.
2. Nakamura K, Teshima T, Imai A, Koizumi M, Mitsuhashi N, Inoue T. Radical radiation therapy for prostate cancer in Japan: A patterns of care study report. Jpn J Clin Oncol 2003;33:122-6.
3. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huan EBS. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
4. Uchida K, Akaza H. Prostate cancer. Gan To Kagaku Ryoho 1999;26:76-82 (in Japanese).
5. Pollack A, Zagars GK. Androgen ablation in addition to radiation therapy for prostate cancer: Is there true benefit? Sem Radiat Oncol 1998;8:95-106.
6. Tyrrell CJ. Adjuvant and neoadjuvant hormonal therapy for prostate cancer. Eur Urol 1999;36:549-58.
7. Vicini FA, Kini VR, Spencer W, Diokno A, Martinez A. The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 1999;43:707-13.
8. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JP, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;45:1013-21.
9. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002;360:103-6.
10. Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry K, et al. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47:617-27.
11. Bolla M, Gonzalez D, Warde P, Dubois JB. Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advance prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;5:295-300.
12. Whittington K, Malkowicz B, Barnes MM, Broderick GA, Van Arsdalen K, Dougherty MJ, et al. Combined hormonal and radiation therapy for lymph node-positive prostate cancer. Urology 1995;46:213-9.
13. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23.
14. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
15. ASTRO consensus statement: Guideline for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
16. Kupelian PA, Mohan DS, Lyons J, Klein EA, Raddy CA. Higher than standard radiation doses (
17. Kim HE, Han SJ, Kasza T, Han K, Choi HS, Palmer KC, et al. Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function. Int J Radiat Oncol Biol Phys 1997;39:731-6.
18. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997;38:1067-70.
19. Sumi M, Ikeda H, Tokuuye K, Kagami Y, Murayama S, Tobisu K, et al. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma. Int J Radiat Oncol Biol Phys 2000;48:519-28.
20. Karasawa K, Kaizu T, Niibe Y, Igaki H, Shinohara M, Tanaka Y, et al. Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men. Int J Radiat Oncol Biol Phys 2003;56:208-12.